Navigation Links
Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Date:8/18/2008

3 in the second quarter of 2008, compared to $109,153 in the second quarter of 2007. General and administrative expenses were $542,043, down from $988,233 in the second quarter of 2007.

Operating income was $2.8 million in the second quarter of 2008 compared to $3.6 million in the second quarter of 2007.

Net income for the second quarter of 2008 was $2.2 million, or $0.05 per diluted share, compared to $3.0 million, or $0.07 per fully diluted share, in the second quarter of 2007.

Adjusting net income for non-cash financing costs associated with its convertible notes and convertible preferred stock, adjusted net income was $2.5 million, or $0.06 per fully diluted share, in the second quarter of 2008, compared to adjusted net income of $3.4 million, or $0.08 per fully diluted share, in the second quarter of 2007.

Six Month Financial Results

Revenues for the first six months of 2008 were $31.1 million, up 47.4% from revenues of $21.1 million in the first six months of 2007. Gross profit was $13.6 million, up 67.8% from gross profit of $8.1 million for the six months of 2007. Gross margin was 43.8%, compared to 38.5% for the first six months of 2007. Operating income was $4.3 million, compared to $4.8 million for the first six months of fiscal 2007.

Net income was $3.2 million, or $0.07 per fully diluted share, compared to $3.9 million, or $0.09 per fully diluted share, for the first six months of fiscal 2007.

Adjusting net income for non-cash financing costs associated with its convertible notes and convertible preferred stock, adjusted net income was $3.9 million, or $0.08 per fully diluted share, for the first six months of 2008, compared to adjusted net income of $4.4 million, or $0.10 per fully diluted share, for the first six months of 2007.

Financial Condition

As of June 30, 2008, Lotus had $3.4 million in cash and equivalents, and $27.0 million of working capital. Total assets were $49.0 million comp
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Draper University, a top program ... announce that for 6 weeks this summer, 39 ... on the Draper University campus in the heart ... focused on entrepreneurship, building real-world skills, and “learning ... its sixth cohort, continues to refresh its curriculum ...
(Date:7/24/2014)... 24, 2014   Cypher Genomics, Inc., ... of Adam Simpson as president and ... and comprehensive annotation and interpretation of individual human ... "Cypher,s technology has the potential to play ... diagnostic accuracy, optimizing therapeutic approaches and reducing adverse ...
(Date:7/24/2014)... San Diego, CA (PRWEB) July 24, 2014 ... in the reporting of molecular diagnostic test results. ... tracking capabilities necessary for the validation and reporting ... in oncology. Molecular diagnostics is a rapidly growing ... for infectious disease, genetic predisposition, cancer, and companion ...
(Date:7/23/2014)... United Arab Emirates (UAE) (PRWEB) July 23, 2014 ... Grace Century recently announced that its biobanking project, ... Vaught , Ph.D. to its growing Advisory Board. ... are very pleased to have Dr. Vaught onboard with ... scientific depth and expertise that Provia’s management team brings ...
Breaking Biology Technology:Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4
... (TCI), a Los,Angeles-based DNA and genomics research and ... office in the heart of Boston,s legal and,financial ... of,chemical and toxic exposures on human health and ... Consulting, TCI now offers a,range of business, financial, ...
... Watson,Pharmaceuticals, Inc. (NYSE: WPI ), a leading ... will provide an,overview of the Company,s business at ... September 10, 2007 at 3:30 p.m. Eastern,Daylight Time. ... can be accessed on Watson,Pharmaceuticals, Investor Relations Web ...
... INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Sept. 4, ... Dow Chemical Company (NYSE: DOW ), and ... Inc. (Nasdaq: EXEL ), announced today,that the ... includes the purchase of selected assets by Dow ...
Cached Biology Technology:Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases 2Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation 2Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation 3
(Date:7/24/2014)... 2014) Scientists at The New York Stem ... closer to creating a viable cell replacement therapy ... , For the first time, NYSCF scientists ... skin samples of patients with primary progressive multiple ... to induce these stem cells into becoming oligodendrocytes, ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... directed by Scripps Research Professor Benjamin Cravatt, Ph.D., ... of The Journal of Biological Chemistry. , The ... previously suggested-for the biosynthesis of neurotransmitter lipids, N-acyl ... anandamide. The high activity of the enzyme a/b ...
... within the cell nucleus and performs one of the ... machines that convert the genetic information carried by messenger ... , Gary Karpen and Jamy Peng, researchers in ... Lawrence Berkeley National Laboratory, have now discovered two pathways ...
... Scripps Research Professor Benjamin Cravatt, Ph.D., is being ... Journal of Biological Chemistry. , The new study ... the biosynthesis of neurotransmitter lipids, N-acyl ethanolamines (NAEs), ... high activity of the enzyme a/b hydrolase4 (Abh4) ...
Cached Biology News:Nanotechnology propels advances in regenerative medicine research 2Regulating the nuclear architecture of the cell 2Regulating the nuclear architecture of the cell 3Regulating the nuclear architecture of the cell 4Regulating the nuclear architecture of the cell 5Brown seaweed contains promising fat fighter, weight reducer 2
... ZMD.473. Immunogen: Synthetic peptide derived ... mouse junctophilin-2. Specificity: Specific for ... (positive controls: mouse skeletal muscle homogenates ... Applications: Western blotting Immunohistochemistry(froz) ImmunofluorescenceStorage: Store ...
Laminin gamma-2 (G-16)...
ABIN-2 Polyclonal Ab 100 ug rabbit polyclonal antibody. Detects ABIN-2 in human/mouse. Tested in WB....
Syd-2 (cL-19)...
Biology Products: